These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8443964)

  • 1. Molecular analysis of C3 allotypes in patients with nephritic factor.
    Finn JE; Mathieson PW
    Clin Exp Immunol; 1993 Mar; 91(3):410-4. PubMed ID: 8443964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of C3 allotypes in patients with systemic vasculitis.
    Finn JE; Zhang L; Agrawal S; Jayne DR; Oliveira DB; Mathieson PW
    Nephrol Dial Transplant; 1994; 9(11):1564-7. PubMed ID: 7870343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of C3 allotypes in Chinese patients with immunoglobulin A nephropathy.
    Finn JE; Li PK; Lai KN; Mathieson PW
    Am J Kidney Dis; 1994 Apr; 23(4):543-6. PubMed ID: 8154490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts.
    Andrews PA; Finn JE; Mathieson PW; Sacks SH
    Transplantation; 1995 Dec; 60(11):1342-6. PubMed ID: 8525532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3.
    Poznansky MC; Clissold PM; Lachmann PJ
    J Immunol; 1989 Aug; 143(4):1254-8. PubMed ID: 2473125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up.
    Schwertz R; Rother U; Anders D; Gretz N; Schärer K; Kirschfink M
    Pediatr Allergy Immunol; 2001 Jun; 12(3):166-72. PubMed ID: 11473682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of donor C3 allotype on late renal-transplantation outcome.
    Brown KM; Kondeatis E; Vaughan RW; Kon SP; Farmer CK; Taylor JD; He X; Johnston A; Horsfield C; Janssen BJ; Gros P; Zhou W; Sacks SH; Sheerin NS
    N Engl J Med; 2006 May; 354(19):2014-23. PubMed ID: 16687714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Production of C3 nephritic factor by cultured lymphocytes derived from glomerulonephritic patients].
    Yamada A; Ohi H; Hatano M
    Nihon Jinzo Gakkai Shi; 1990 Apr; 32(4):373-8. PubMed ID: 2376910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
    Levy Y; George J; Yona E; Shoenfeld Y
    Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of polymorphisms of human complement component C3.
    Botto M; Fong KY; So AK; Koch C; Walport MJ
    J Exp Med; 1990 Oct; 172(4):1011-7. PubMed ID: 1976733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 alleles in diseases associated with C3 activation.
    Welch TR; Berry A
    Dis Markers; 1987 Jun; 5(2):81-7. PubMed ID: 3502986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies.
    Skattum L; Mårtensson U; Sjöholm AG
    J Intern Med; 1997 Dec; 242(6):455-64. PubMed ID: 9437406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 nephritic factor and mesangiocapillary glomerulonephritis.
    Williams DG
    Pediatr Nephrol; 1997 Feb; 11(1):96-8. PubMed ID: 9035182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis.
    Power DA; Ng YC; Simpson JG
    Q J Med; 1990 Apr; 75(276):387-98. PubMed ID: 2385743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of C3 nephritic factor by cultured lymphocytes derived from a patient with partial lipodystrophy.
    Yamada A; Ohi H; Okano K; Watanabe S; Seki M; Hatano M; Koitabashi Y
    J Clin Lab Immunol; 1988 Sep; 27(1):35-7. PubMed ID: 3251045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.
    Bennett WM; Bardana EJ; Wuepper K; Houghton D; Border WA; Götze O; Schreiber R
    Am J Med; 1977 May; 62(5):757-60. PubMed ID: 860726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
    Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
    J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complement abnormalities of lipodystrophy.
    Sissons JG; West RJ; Fallows J; Williams DG; Boucher BJ; Amos N; Peters DK
    N Engl J Med; 1976 Feb; 294(9):461-5. PubMed ID: 1246331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
    Habib R; Lévy M; Gubler MC; Broyer M; Habib M
    Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody.
    Koch C; Behrendt N
    Immunogenetics; 1986; 23(5):322-5. PubMed ID: 3519446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.